Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, … Read more
Tekla Life Sciences Investors (HQL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.003x
Based on the latest financial reports, Tekla Life Sciences Investors (HQL) has a cash flow conversion efficiency ratio of -0.003x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.04 Million) by net assets ($395.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tekla Life Sciences Investors - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Tekla Life Sciences Investors's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tekla Life Sciences Investors Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tekla Life Sciences Investors ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ALMONTY INDUSTRY O.N.
F:ALI1
|
N/A |
|
MODUS THERAPEUTICS HLDG
F:99Z
|
N/A |
|
Mcdermott International Ltd
PINK:MCDIF
|
N/A |
|
WUESTENROT & WUERTT - Dusseldorf Stock Exchang
DU:WUW
|
N/A |
|
Sanyo Special Steel Co., Ltd.
PINK:SYPLF
|
0.038x |
|
Scanwolf Corporation Bhd
KLSE:7239
|
-0.163x |
|
UNIQA INSURANCE GR
BE:UN9
|
0.067x |
|
BBI BUERG BRAU IMMO
MU:BBI
|
N/A |
Annual Cash Flow Conversion Efficiency for Tekla Life Sciences Investors (1996–2025)
The table below shows the annual cash flow conversion efficiency of Tekla Life Sciences Investors from 1996 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $513.66 Million | $31.71 Million | 0.062x | +4366559052.82% |
| 2021-09-30 | $523.44 Million | $-0.74 | 0.000x | +12.40% |
| 2019-09-30 | $384.16 Million | $-0.62 | 0.000x | +100.00% |
| 2014-09-30 | $444.09 Million | $-52.57K | 0.000x | -477.75% |
| 2013-09-30 | $302.29 Million | $9.47K | 0.000x | -99.97% |
| 2012-09-30 | $227.08 Million | $21.11 Million | 0.093x | -86.60% |
| 2011-09-30 | $170.60 Million | $118.30 Million | 0.693x | +9075.24% |
| 2010-09-30 | $251.40 Million | $1.90 Million | 0.008x | -85.55% |
| 2009-09-30 | $248.60 Million | $13.00 Million | 0.052x | +23.11% |
| 2008-09-30 | $277.80 Million | $11.80 Million | 0.042x | +453.59% |
| 2007-09-30 | $308.00 Million | $-3.70 Million | -0.012x | -53.37% |
| 2006-09-30 | $268.10 Million | $-2.10 Million | -0.008x | +43.87% |
| 2005-09-30 | $229.30 Million | $-3.20 Million | -0.014x | +16.35% |
| 2004-09-30 | $191.80 Million | $-3.20 Million | -0.017x | -32.36% |
| 2003-09-30 | $190.40 Million | $-2.40 Million | -0.013x | +23.59% |
| 2002-09-30 | $157.60 Million | $-2.60 Million | -0.016x | -86.77% |
| 2001-09-30 | $215.10 Million | $-1.90 Million | -0.009x | +48.04% |
| 1998-09-30 | $100.00 Million | $-1.70 Million | -0.017x | -49.60% |
| 1997-09-30 | $132.00 Million | $-1.50 Million | -0.011x | +6.74% |
| 1996-09-30 | $123.10 Million | $-1.50 Million | -0.012x | -- |